| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_930dbfaf9af0027ba4121c0a7c4288de |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55516
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39 |
| filingDate |
2014-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af6b0e03d7d025437f2dbfe8ea388deb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b92bcc425f5779c510b5081be5533aeb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5bf100cc7f09dccf122570f86a231a7d |
| publicationDate |
2015-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2958588-A1 |
| titleOfInvention |
Combination of vaccination and inhibition of the pd-1 pathway |
| abstract |
The present invention relates to a vaccine/inhibitor combination comprising an RNA vaccine comprising at least one RNA comprising at least one open reading frame (ORF) coding for at least one antigen and a composition comprising at least one PD-1 pathway inhibitor, preferably directed against PD-1 receptor or its ligands PD-L1 and PD-L2. The present invention furthermore relates to a pharmaceutical composition and a kit of parts comprising the components of such a vaccine/inhibitor combination. Additionally the present invention relates to medical use of such a vaccine/inhibitor combination, the pharmaceutical composition and the kit of parts comprising such a vaccine/inhibitor combination, particularly for the prevention or treatment of tumor or cancer diseases or infectious diseases. Furthermore, the present invention relates to the use of an RNA vaccine in therapy in combination with a PD-1 pathway inhibitor and to the use of a PD-1 pathway inhibitor in therapy in combination with an RNA vaccine. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11110157-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10323091-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4035659-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10450373-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10307472-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10117920-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3292873-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11458195-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10434158-B2 |
| priorityDate |
2013-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |